Eytan Ruppin received his M.D. and Ph.D. from Tel-Aviv University where he has served as a professor of Computer Science & Medicine since 1995, conducting computational multi-disciplinary research spanning computational neuroscience, natural language processing, machine learning and systems biology. In 2014 he joined the University of Maryland as director of its center for bioinformatics and computational biology (CBCB). In 2018 he moved to the NCI where he founded and is chief of its Cancer Data Science Lab (CDSL, https://ccr.cancer.gov/cancer-data-science-laboratory). His research is focused on developing new AI-driven approaches for fast and readily available patients survival and response biomarkers that lay the basis for democratizing cancer patients care. Eytan is a fellow of the International Society for Computational Biology (ISCB), a recipient of the NCI Director award for his work on precision oncology (2022), the DeLano award for computational biosciences for his work on synthetic lethality (2023) and the NIH director award for developing new computational paradigms for precision oncology (2024). He is a member of GSK Oncology, ProCan and WIN consortium scientific advisory boards and a co-founder of a few precision medicine startup companies.